Axsome Therapeutics, Inc.·4

Jun 9, 5:18 PM ET

Mahony Susan 4

4 · Axsome Therapeutics, Inc. · Filed Jun 9, 2026

Research Summary

AI-generated summary of this filing

Updated

Axsome (AXSM) Director Susan Mahony Receives RSU Award

What Happened
Susan Mahony, a director of Axsome Therapeutics (AXSM), received a grant of 1,721 restricted stock units (RSUs) on June 5, 2026. The Form 4 records the acquisition as a derivative award at $0.00 (typical for RSU grants, which are contingent rights to shares rather than open-market purchases).

Key Details

  • Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (timely filing). Accession: 0001193125-26-264040.
  • Transaction type/code: Award/Grant (A). Reported price: $0.00; reported value on Form 4: $0.
  • Grant size: 1,721 RSUs. Each RSU converts to one share of common stock upon vesting (Footnote F1).
  • Vesting: RSUs vest in full on the one-year anniversary of the grant (Footnote F2).
  • Shares owned after transaction: Not specified in the summarized data provided.

Context
RSU grants are compensation awards that give the holder a contingent right to receive shares in the future; they do not represent an immediate cash purchase or sale. Because these awards typically vest over time, they are routine compensation and not a direct market signal like an open-market purchase or sale.

Insider Transaction Report

Form 4
Period: 2026-06-05
Mahony Susan
Director
Transactions
  • Award

    Restricted Stock Units

    [F1][F2]
    2026-06-05+1,7211,721 total
    Common Stock (1,721 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The RSUs vest in full on the one-year anniversary of the date of grant.
Signature
/s/ Nick Pizzie, Attorney-in-Fact|2026-06-09

Documents

1 file
  • 4
    ownership.xmlPrimary

    4